Last updated on April 2013

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS)


Brief description of study

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS)

Detailed Study Description

Patient Inclusion Criteria:

  • Ages 18+
  • RLS diagnosis
  • 15 nights or more in past month with RLS symptoms
  • Must stop all RLS medications 2 weeks prior
  • No Horizant usage in past
  • Men or women 18 years of age or older
  • History of RLS symptoms for at least 15 nights/month
  • Documented RLS symptoms, using the 7-day RLS Symptom Record, for at least 4 of the 7 consecutive evenings/nights during the night
  • Total RLS severity score of 15 or greater on the International RLS (IRLS) Rating Scale at Visit 1 and at Visit 2
  • Discontinuation of dopamine agonists and/or gabapentin , or other treatments for RLS (e.g. opioids, benzodiazepines) at least 2 weeks prior to Baseline
  • If taking any prescription medication, therapy must have been stabilized for at least 3 months prior to Screening with no anticipated changes for the duration of the study
  • Female subjects are eligible if of non-childbearing potential or not lactating, has a negative pregnancy, and agrees to use a highly effective method for avoiding pregnancy
  • Body mass index of 34 or below
  • Estimated creatinine clearance of ≥60 mL/min
  • Provides written consent in accordance with all applicable regulatory requirements

Patient Exclusion Criteria:

  • History of a sleep disorder that may affect the assessment of RLS
  • History of RLS symptom augmentation or end-of-dose rebound with previous dopamine agonist treatment
  • Neurologic disease or movement disorder
  • Other medical conditions or drug therapy that could affect RLS efficacy assessments or may present a safety concern
  • Have clinically significant or unstable medical conditions
  • Have active suicidal plan/intent or has had active suicidal thoughts in the past 6 months; has a history of suicide attempt

Clinical Study Identifier: TX136795

Contact Investigators or Research Sites near you

Start Over

Kathleen Carlson

Axiom Clinical Research of Florida
Tampa, FL USA
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.